Evaluation of low dose alpha-interferon (Roferon-A) in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.

@article{Marshall1995EvaluationOL,
  title={Evaluation of low dose alpha-interferon (Roferon-A) in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.},
  author={M. Ernest Marshall and M Wolf and E. David. Crawford and Ian M. Thompson and Robert Flanigan and Stanley P. Balcerzak and Fredrick J. Meyers},
  journal={Cancer biotherapy},
  year={1995},
  volume={10 3},
  pages={205-9}
}
Alpha-interferon (IFN) has been shown to produce antitumor responses among patients with advanced renal cell carcinoma. While responses have been observed over a range of IFN doses and schedules, significant toxicities can be experienced from relatively high doses given three to five times weekly. Based upon the report of a pilot study indicating that low… CONTINUE READING